Healthcare Industry News: NPWT
News Release - January 18, 2018
Smith & Nephew's Episode of Care Assurance Program (eCAP) reduces hospital readmission following total joint replacement surgeryLONDON, Jan. 18, 2018 -- (Healthcare Sales & Marketing Network) -- Smith & Nephew (NYSE: SNN; LSE: SN), the global medical technology business, today announces results showing a near 75% decrease in readmission rates for joint arthroplasties (TJA) conducted under its Episode of Care Assurance Program (eCAP).
Working with Provider PPI, eCAP combines Smith & Nephew's leading hip and knee implants with its PICO™ Negative Pressure Wound Therapy and ACTICOAT™ Flex 7 Antimicrobial Barrier Dressings. These products are applied post-surgery; PICO may help protect the incision by reducing seroma and hematoma fluid collections, reducing edema and lateral tension and improving perfusion.1-5 ACTICOAT Flex 7, which contains Nanocrystalline Silver, provides an effective barrier to microbial contamination to help deter surgical site infections.6
Over the past year over 1,000 TJAs have been conducted under the eCAP program with only two readmissions, a readmission rate of only 0.20% as compared to published rates of 5.3% or more.7
"As healthcare systems move from fee for service to pay for value, healthcare providers are increasingly responsible for the episode of care for the patient," said Glenn Warner, President Smith & Nephew US. "eCAP can help enable providers to reduce costly readmissions after TJA by adding class-leading wound care products to help manage surgical incisions. We are proud to support our customers with innovative programs that deliver improved care in a large-scale, real-world setting."
Smith & Nephew worked with Provider PPI, a group purchasing organization, to implement this program at Provider PPI's client facilities in late 2016 with positive results, and is now serving 16 facilities across the US.
"Adding PICO and Acticoat products from Smith & Nephew to our TJA cases has been a great win for our health system clients and their patients," said Paul Gallagher, Vice President, Provider PPI. "I am extremely pleased to see our readmission rate drop to nearly zero. In Smith & Nephew we've worked with a comprehensive product solutions partner that's willing to stand behind its product portfolio."
- Lumb H. Bacterial barrier testing (wet-wet) of PICO™ dressing with a 7 day test duration against S. marcescens.
- Wilkes RP, et al. Closed incision management with negative pressure wound therapy (CIM): Biomechanics. Surg Innov 2011.
- Karlakki S, et al. Negative Pressure Wound Therapy for management of the surgical incision in Orthopedic surgery. A review of evidence and mechanisms for an emerging indication. Bone Joint Res 2013; 2: 276-284.
- Canonico S, et al. Therapeutic possibilities with portable NPWT. Initial multidisciplinary observations with the negative pressure device. Acta Vulnol 2012; 10: 57-66.
- Selvaggi F, et al. New advances in Negative Pressure Wound Therapy (NPWT) for surgical wounds of patients affected with Crohn's Disease. Surg Tech Int 2014; XXIV: 83- 89.
- Burrell et al. Efficacy of Silver-Coated Dressing as Bacterial Barriers in a Rodent Burn Sepsis Model, WOUNDS 1999; 11(4):64-71.
- Unplanned Readmission After Total Joint Arthroplasty: Rates, Reasons, And Risk Factors - The Journal Of Bone & Joint Surgery - jbjs.org - Volume 95-A - Number 20 October 16, 2013.
About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2016 were almost $4.7 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE: SNN)
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.
™Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.
Source: Smith & Nephew
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsSmith & Nephew to expand Real Intelligence digital ecosystem and CORI(TM) Surgical System with total hip arthroplasty
Smith & Nephew launches new total ankle and total shoulder replacement technologies; showcases recently acquired Extremity Orthopaedics portfolio at AAOS
New data underscores material benefits of Smith & Nephew's OXINIUM(TM) DH Technology and OR3O(TM) Dual Mobility System for total hip arthroplasty versus Cobalt Chrome liners